Private company
Veloxis Pharmaceuticals
Logo: http://ir.veloxis.com/static-files/6d32b377-2062-4471-9afd-d8743f1c08fd, Non-free logo, via Wikipedia3
Pharmaceutical company
Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro.2 From Wikipedia, CC BY-SA 4.0
Last updated Oct 16, 2026.
Overview
- Tickeron Nasdaq Copenhagen A/S1
- HeadquartersAmerika Plads1
- Websitewww.veloxis.com
- Legal formaktieselskab1
- Listed onNasdaq Copenhagen A/S (VELO)1
See how the biggest companies compare on our leaderboards
Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. The company was founded in 2002 as a spin-off from H. Lundbeck A/S. Veloxis is headquartered in Hørsholm, Denmark, with an office in Cary, North Carolina.2
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
A 3D Printer And Parts brought in 85% of the revenue Veloxis Pharmaceuticals broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| A 3D Printer And Parts | $25.4M | $39.2M |
| Support Services | $9.6M | $6.2M |
| Other | $5.0M | $524.0K |
| Recurring Payment | $1.1M | $70.0K |
Regions
Americas brought in 87% of the revenue Veloxis Pharmaceuticals broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| Americas | $39.9M | $39.9M |
| Europe | $839.0K | $4.5M |
| Other Locations | $256.0K | $1.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue83¢$53.4M
- Research and development17¢$10.7M
- Income tax0¢$117.0K
Out of $46.0M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | $46.0M | $41.0M |
| Total Revenue | $46.0M | $41.0M |
| Cost of revenue | $53.4M | $43.1M |
| Gross loss | -$7.4M | -$2.1M |
| Research and development | $10.7M | $15.5M |
| Selling and marketing | $6.8M | $12.9M |
| General and administrative | $30.1M | $48.4M |
| Total operating expenses | $47.5M | $76.7M |
| Loss from operations | -$54.9M | -$78.8M |
| Interest expense | -$4.4M | -$16.0M |
| (Loss) gain on fair value of warrants | -$1.1M | $32.1M |
| Gain on fair value of contingent earnout liabilities | $10.0K | $1.4M |
| Loss on warrant cancellation | -$11.4M | $0 |
| Loss on debt extinguishment | $0 | -$4.9M |
| Other income (expense), net | $526.0K | -$3.6M |
| Loss before income taxes | -$71.2M | -$69.8M |
| (Provision) benefit for income taxes | -$117.0K | $20.0K |
| Net loss | -$71.4M | -$69.7M |
| Net income (loss) per share basic | -$4.33 | -$82.32 |
| Net income (loss) per share Diluted | -$4.33 | -$82.32 |
| Shares used in computing net loss per share basic | 16.5M shares | 847.3K shares |
| Shares used in computing net loss per share diluted | 16.5M shares | 847.3K shares |
| Net unrealized holding gain on available-for-sale investments | $0 | $96.0K |
| Total comprehensive loss | -$71.4M | -$69.6M |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $39.0M | ||
| Accounts receivable, net | $6.3M | ||
| Inventories, net | $27.1M | ||
| Contract assets | $2.0M | ||
| Prepaid expenses and other current assets | $5.7M | ||
| Total current assets | $80.1M | ||
| Property and equipment, net | $13.1M | $2.8M | $2.9M |
| Equipment subject to operating lease, net | $1.6M | ||
| Other assets | $10.5M | ||
| Total assets | $105.3M | $93.7M | $78.4M |
| Accounts payable | $10.3M | ||
| Accrued expenses and other current liabilities | $7.9M | ||
| Debtcurrent portion | $6.3M | ||
| Contract liabilities | $9.3M | ||
| Total current liabilities | $33.8M | ||
| Long-term debtless current portion | $24.7M | ||
| Contingent earnout liabilities (Note 10) | $1.0K | ||
| Warrant liabilities (Note 10) | $109.0K | ||
| Other noncurrent liabilities | $8.6M | ||
| Total liabilities | $67.2M | ||
| Common stock, $0.00001 par value - 500,000,000 shares authorized at December 31, 2025 and 2024, respectively, 24,607,630 and 12,993,962 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $5.0K | ||
| Additional paid-in capital | $536.3M | $506.2M | $486.4M |
| Accumulated other comprehensive loss | $0 | ||
| Accumulated deficit | -$498.1M | -$476.2M | -$465.1M |
| Total stockholders equity | $38.2M | $29.9M | $21.4M |
| Total liabilities and stockholders equity | $105.3M | $93.7M | $78.4M |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | ||
| Common stock, shares issued | 24.6M shares | ||
| Common stock, shares outstanding | 24.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$71.4M | -$69.7M |
| Depreciation and amortization | $3.4M | $4.8M |
| Amortization of debt discount and deferred financing costs | $192.0K | $13.6M |
| Stock-based compensation | $9.5M | $11.8M |
| Gain on exchange of debt for common stock | $0 | -$2.6M |
| Change in fair value of warrants | $1.1M | -$32.1M |
| Change in fair value of contingent earnout liabilities | -$10.0K | -$1.4M |
| Impairment of equipment subject to operating lease | $1.1M | $0 |
| Loss on warrant cancellation | $11.4M | $0 |
| Reserve for excess and obsolete inventory | $7.0M | $7.2M |
| Non-cash cost of issuance of common stock warrants on BEPO Offering | $0 | $1.3M |
| Loss on debt extinguishment | $0 | $7.5M |
| Non-cash warrant issuance in connection with August warrant inducement | $0 | $2.4M |
| Provision for credit loss related to contract assets | $1.4M | $0 |
| Provision for credit loss related to trade accounts receivable | $1.9M | $2.8M |
| Non-cash lease expense | $139.0K | $134.0K |
| Loss on sale/disposal of fixed assets | $24.0K | $11.0K |
| Realized loss on available-for-sale securities | $0 | $23.0K |
| Accounts receivable | -$4.4M | $3.1M |
| Inventories | $24.4M | $6.1M |
| Contract assets | -$2.9M | $7.0M |
| Prepaid expenses and other current assets | -$3.4M | $1.8M |
| Other assets | $2.0M | $4.0M |
| Accounts payable | -$15.3M | -$743.0K |
| Accrued expenses and other liabilities | $8.0M | -$2.6M |
| Contract liabilities | -$1.0M | $5.2M |
| Other noncurrent liabilities | -$346.0K | -$2.2M |
| Net cash used in operating activities | -$27.3M | -$32.7M |
| Purchase of property and equipment | -$2.7M | -$9.0K |
| Reimbursement of previously incurred leasehold expenditures | $0 | $1.1M |
| Sales of property and equipment | $0 | $20.0K |
| Sales of available-for-sale securities | $0 | $3.2M |
| Proceeds from maturity of available for sale investments | $0 | $3.5M |
| Net cash (used in) provided by investing activities | -$2.7M | $7.8M |
| Proceeds from secured convertible notes | $15.0M | $500.0K |
| Repayment of secured notes | -$2.6M | -$11.8M |
| Proceeds from equipment loan | $10.0M | $0 |
| Repayment of equipment loan | -$311.0K | $0 |
| Issuance cost for equipment loan | -$19.0K | $0 |
| Gross proceeds from December 2025 PIPE Offering | $30.0M | $0 |
| Payment for issuance cost related to December 2025 PIPE Offering | -$2.0M | $0 |
| Gross proceeds from August 2025 Offering | $20.1M | $0 |
| Payment for issuance cost related to August 2025 Offering | -$2.3M | $0 |
| Proceeds from capital raise - August Warrant Inducement | $0 | $1.7M |
| Gross proceeds from BEPO Offering | $0 | $12.0M |
| Payments for issuance cost related to the BEPO Offering | $0 | -$1.3M |
| Issuance of common stock upon exercise of stock options | $0 | $315.0K |
| Net cash provided by financing activities | $67.8M | $1.5M |
| Effect of exchange rate on cash and cash equivalents | $5.0K | -$4.0K |
| Net change in cash and cash equivalents | $37.8M | -$23.5M |
| Cash paid for interest | $1.1M | $1.2M |
| Cash paid for income taxes for foreign subsidiary | $117.0K | $0 |
| Unpaid liabilities related to property and equipment, net | $742.0K | $3.1M |
| Equipment subject to operating lease, net returned to inventories, net | $653.0K | $2.2M |
| Warrant cancellation upon issuance of common stock | $3.2M | $0 |
| Operating lease right-of-use assets recorded in exchange for lease obligation | $864.0K | $0 |
| Transfer of property and equipment, net to inventories, net | $1.6M | $0 |
| Unpaid purchase of inventories, net | $6.3M | $3.5M |
Products and brands
MeltDose Technology Platform
MeltDose works by incorporating a drug substance with low water solubility into a "meltable" vehicle. It is then sprayed on an inert particulate carrier using fluid bed equipment.
The melt is solidified when deposed on a particle carrier, and thus captures the active drug in a solid dispersion either as a solid solution or in a nano-crystalline state. The particle size is then increased by controlling and optimizing the product temperature and feed rate of the melt.
The granulate can be directly compressed into tablets without additional processing steps besides blending with a lubricant. In addition, the technology allows for customization of the release profile.
Once in tablet form, the dissolution profile and the particle size of drugs manufactured using MeltDose® technology remain stable allowing for a long shelf-life.
Read the full text
Product Pipeline
Source:
LCP-Tacro (tacrolimus) is a once-daily dosage version of tacrolimus for prevention of rejection in organ transplant patients in two Phase 3 clinical trials in kidney transplant patients. The first study in stable transplant patients showed that LCP-Tacro was non-inferior in efficacy and safety compared to twice-daily tacrolimus (Prograf®) [ESOT REF]. The second Phase 3 clinical trial in de novo patients is ongoing. A Phase 3b clinical trial evaluating whether patients experiencing symptomatic tremor on twice-daily tacrolimus demonstrate improvement in their tremors when switched to LCP-Tacro was published in 2017, and demonstrated that LCP-Tacro resulted in improvements on a number of patient-reported outcomes.
FENOGLIDE (fenofibrate) for dyslipidemia, marketed in the U.S. by Santarus, Inc.
From Wikipedia’s article on Veloxis Pharmaceuticals, shared under CC BY-SA 4.0.4
Subsidiaries and ownership
Owners
From Wikidata.1
Timeline
- Mar 21, 2002Founded Founded1
Links
- Websitewww.veloxis.com1
- WikipediaVeloxis Pharmaceuticals
- WikidataQ7919317
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2WikipediaVeloxis Pharmaceuticals on Wikipedia
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11